EUVIMEDEUVIMED entdecken
Crossref

Human Immunodeficiency Virus Seroconversion Among Men Who Have Sex With Men Who Use Event-Driven or Daily Oral Pre-Exposure Prophylaxis (CohMSM-PrEP): A Multi-Country Demonstration Study From West Africa

Christian Laurent, Issifou Yaya, Benjamin Cuer, Luis Sagaon-Teyssier, Ephrem Mensah, Ter Tiero Elias Dah, Alou Coulibaly, Malan Jean-Baptiste Kouamé, Gilles Peytavin, Laetitia Serrano, August Eubanks, Issa Traoré und 9 weitere

Clinical Infectious Diseases · 22.08.2023 · 77 (4) · 606-614

DOI: 10.1093/cid/ciad221 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 13.04.2023. Verfasst von Christian Laurent und 20 weiteren Autor:innen. Beteiligte Einrichtung: TransVIHMI, Univ Montpellier, IRD, Inserm, Montpellier, France. Hauptthemen laut MEDLINE: HIV Infections, HIV Seropositivity, Pre-Exposure Prophylaxis, Anti-HIV Agents. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: ANRS, Nord, Sida.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Data on human immunodeficiency virus (HIV) seroconversion among men who have sex with men (MSM) using pre-exposure prophylaxis (PrEP) in West Africa are needed. This study aimed to document HIV seroconversion and associated determinants, PrEP adherence, plasma drug concentrations, and HIV drug resistance in MSM using event-driven or daily PrEP in Burkina Faso, Côte d’Ivoire, Mali, and Togo.

Methods

A prospective cohort study was conducted in 2017–2021 among HIV-seronegative MSM aged 18 or over who were at high risk of HIV infection. Participants could choose between event-driven and daily PrEP, switch regimens, and discontinue or restart PrEP. The determinants of HIV incidence were investigated using a multivariate mixed-effects Poisson regression analysis.

Results

A total of 647 participants were followed for a total time of 1229.3 person-years. Of 5371 visits, event-driven PrEP was chosen in 3873 (72.1%), and daily PrEP in 1400 (26.1%). HIV incidence was 2.4 per 100 person-years (95% confidence interval [CI] 1.5–3.6) for event-driven PrEP, and 0.6 per 100 person-years (95% CI .1–2.3) for daily PrEP (adjusted incidence rate ratio 4.40, 95% CI 1.00–19.36, P = .050). Adequate adherence was lower with event-driven than daily PrEP (44.3% vs 74.9%, P < .001). Plasma drug concentrations were undetectable in 92 (97.9%) of the 94 measures taken for 23 participants who seroconverted. Only 1 participant had resistance to PrEP drugs.

Conclusions

HIV seroconversions mainly occurred in participants who chose event-driven PrEP. The study's data highlighted major difficulties with adherence to this regimen. Improving adherence to event-driven PrEP constitutes a major research and public health priority in this context.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsHIV SeropositivityPre-Exposure ProphylaxisAnti-HIV AgentsSexual and Gender MinoritiesMaleHumansHomosexuality, MaleProspective StudiesSeroconversionBurkina FasoHIV

Stichwörter der Autor:innen

AfricaHIVMSMPrEPseroconversion

Substanzen

Anti-HIV Agents

Autor:innen und Institutionen

  • TransVIHMI, Univ Montpellier, IRD, Inserm, Montpellier, France.
  • Inserm, IRD, Aix-Marseille Univ, SESSTIM (Sciences Economiques et Sociales de la Santé et Traitement de l'Information Médicale), ISSPAM, Marseille, France.
  • Espoir Vie Togo, Lomé, Togo.
  • Association African Solidarité, Ouagadougou, Burkina Faso.
  • Université de Ouahigouya, UFR Sciences de la santé, Ouahigouya, Burkina Faso.
  • ARCAD Santé PLUS, Bamako, Mali.

Förderung

  • ANRS
  • Nord
  • Sida
  • Sidaction

Zitieren

APA

Laurent, C., Yaya, I., Cuer, B., Sagaon-Teyssier, L., Mensah, E., Dah, T. T. E., Coulibaly, A., Kouamé, M. J., Peytavin, G., Serrano, L., Eubanks, A., Traoré, I., Diallo, F., Riegel, L., Rojas Castro, D., Dagnra, C. A., Anoma, C., Vuylsteke, B., Dembélé Keita, B., …, & CohMSM-PrEP Study Group (2023). Human Immunodeficiency Virus Seroconversion Among Men Who Have Sex With Men Who Use Event-Driven or Daily Oral Pre-Exposure Prophylaxis (CohMSM-PrEP): A Multi-Country Demonstration Study From West Africa. Clinical Infectious Diseases, 77(4), 606-614. https://doi.org/10.1093/cid/ciad221

Vancouver

Laurent C, Yaya I, Cuer B, Sagaon-Teyssier L, Mensah E, Dah TTE, et al. Human Immunodeficiency Virus Seroconversion Among Men Who Have Sex With Men Who Use Event-Driven or Daily Oral Pre-Exposure Prophylaxis (CohMSM-PrEP): A Multi-Country Demonstration Study From West Africa. Clinical Infectious Diseases. 2023;77(4):606-614. doi:10.1093/cid/ciad221

BibTeX
@article{Laurent2023,
  author = {Laurent, Christian and Yaya, Issifou and Cuer, Benjamin and Sagaon-Teyssier, Luis and Mensah, Ephrem and Dah, Ter Tiero Elias and Coulibaly, Alou and Kouamé, Malan Jean-Baptiste and Peytavin, Gilles and Serrano, Laetitia and Eubanks, August and Traoré, Issa and Diallo, Fodié and Riegel, Lucas and Rojas Castro, Daniela and Dagnra, Claver A and Anoma, Camille and Vuylsteke, Bea and Dembélé Keita, Bintou and Spire, Bruno and CohMSM-PrEP Study Group, CohMSM-PrEP Study Group},
  title = {Human Immunodeficiency Virus Seroconversion Among Men Who Have Sex With Men Who Use Event-Driven or Daily Oral Pre-Exposure Prophylaxis (CohMSM-PrEP): A Multi-Country Demonstration Study From West Africa},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  volume = {77},
  number = {4},
  pages = {606--614},
  doi = {10.1093/cid/ciad221}
}
Kostenlos starten →